In this slideshow, we revisit some of the most notable research findings in rheumatology featured in recent weeks. We begin with a study that shows TNF inhibitor treatment may not heighten cancer risk.
Three studies presented this weekend at EULAR in Madrid suggest that being overweight or obese can heighten the severity or arthritic disease.
The overall risk of cancer in psoriatic arthritis patients who are treated with TNF inhibitors doesn’t appear to be linked to their treatment, according to a study presented EULAR this weekend.
A 24-week trial of tildrakizumab to treat the skin and joint conditions associated with psoriatic arthritis shows promise as a possible new treatment, shows a study presented at EULAR.
EULAR 2019 wraps this weekend in Madrid. In this slideshow, we highlight some of the most noteworthy findings, beginning with a possible new treatment combination for patients who have both gout and kidney disease.
A high consumption of ultra-processed foods (i.e. almost any consumable food item, except fresh fruits and vegetables) is associated with an increased risk of cardiovascular disease and mortality, show two studies in BMJ.
Etanercept is a safe, well-tolerated medication for treating pediatric patients with extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthritis, and psoriatic arthritis, according to the results for a new study.
In April, the FDA approved the etanercept biosimilar etanercept-ykro (Eticovo, Samsung Bioepis) for the same indications as its reference product Enbrel.
Psoriasis patients have a lower risk of serious infection with specific biologic and non-biologic medications than with methotrexate, based on new research results.
From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics.